SBIR and STTR Success Story for
Menssana Research, Inc

(Information Posted/Updated on 06/22/2004)

Menssana Research, Inc
1 Horizon Road, Suite 1415
Fort Lee, NJ  07024

Contact:    Michael Phillips MD
Phone:      201-886- 7004
Fax:          201-886-7004
Web Site:

Project Title:  Breath tests for detection of disease
Related Award(s):  2R44HL59715, 1R43CA77098-01, 1R41CA81842-01, 1R41RR1323301, 1R43AI52504-01, 1R43DE015923-0, 5R44HL70411-03
Technology Developed:
We developed a highly sensitive test to detect low concentrations of volatile organic compounds in breath. Clinical studies have shown that this breath test provides a sensitive and specific marker of heart transplant rejection, lung cancer, breast cancer and pulmonary tuberculosis. The Food & Drug Administration has approved the breath test for heart transplant rejection (Heartsbreath) for clinical use.

Key Words:  breath, volatile, heart transplant, lung cancer, breast cancer, tuberculosis.
Uses of Technology/Products/Service:
Breath testing could provide a new way to detect diseases such as lung cancer and breast cancer in their earliest stages, when treatment is most effective. Breath tests are completely safe and painless, as well as less expensive than competing technologies. Potentially, these new breath tests could save lives and reduce the cost of health care.